期刊
MEDICAL MICROBIOLOGY AND IMMUNOLOGY
卷 197, 期 2, 页码 117-123出版社
SPRINGER
DOI: 10.1007/s00430-008-0074-5
关键词
cytomegalovirus vaccine; rhesus macaques; modified vaccinia Ankara virus
资金
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD056051] Funding Source: NIH RePORTER
- NATIONAL CANCER INSTITUTE [P01CA030206, R01CA077544, P30CA033572] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI062496, R01AI063356] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA077544, CA33572, CA30206-PRJ3, CA077544] Funding Source: Medline
- NCRR NIH HHS [RR000169] Funding Source: Medline
- NIAID NIH HHS [AI063356, AI062496] Funding Source: Medline
- NICHD NIH HHS [R21 HD056051] Funding Source: Medline
A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据